Risperidone-induced hyperprolactinemia in adolescents: A case series

Journal of Clinical Psychiatry

Volumn 67, Issue 7, 2006, Pages 1110-1113

  Madhusoodanan, Subramoniam ^a,c   Moise, Despina ^b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b PALMERSTON NORTH HOSPITAL   (New Zealand)

^c ST JOHN S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AMENORRHEA; ANAMNESIS; ARTICLE; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; GYNECOMASTIA; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; MAJOR DEPRESSION; MALE; OUTPATIENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 33747200815     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0714     Document Type: Article

References (25)

1. Ehrinpreis MN, Dhar R, Narula A. Cimetidine-induced galactorrhea. Am J Gastroenterol 1989;84:563-565
2. Dombrowski RC, Romeo JH, Aron IX. Verapamil-induced hypeiprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother 1995;29:999-1001
3. Shioiri T, Kita N, Takahashi S. Two cases of alprazolam-induced hyperprolactinemia in patients with panic disorder. Int Clin Psychophamiacol 1996;11:149-152
4. Lynch A, Madjlessi A. Gynecomastia-galactorrhea during treatment with mirtazapine [letter] [in French]. Presse Med 2004;33:458
5. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-2314
6. American Psychiatric Association. APA Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2004. Arlington, Va: American Psychiatric Publishing, Inc; 2004:350-351
7. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004;65:1491-1498
8. Kearns AE, Goff DC, Hayden DL, et al. Risperidone-associated hyperprolactinemia. Endocr Pract 2000;6:425-429
9. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(suppl 2):55-68
10. Meaney AM, O'Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 2002;71:979-992
11. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002;63(suppl 4):56-62
12. Meaney AM, O'Keane V. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising antipsychotic medication. J Psychopharmacol 2003;17:455-458
13. Abraham G, Paing WW, Kaminski J, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 2003;160:1618-1620
14. Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 2004;14:350-358
15. Haddad APM, Hellewell JS, Wieck A. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. J Psychopharmacol 2001;15:293-295
16. Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004;65:187-190
17. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001;11:435-440
18. Galli-Tsinopoulou A, Nousia-Arvanitakis S, Mitsiakos G, et al. Osteopenia in children and adolescents with hyperprolactinemia. J Pediatr Endocrinol Metab 2000;13:439-441
19. Miller KK. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectr 2004;9(8 suppl 7):28-32
20. Ereshefsky L, LaCombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(suppl 3):S80-S88
21. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
22. Jeste DV, Barak Y, Madhusoodanan S, et al. International multisite double-blind trial of the atypical antipsychotic risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 2003;11:638-647
23. Gupta S, Frank B, Madhusoodanan S. Risperidone-associated galactorrhea in a male teenager [letter]. J Am Acad Child Adolesc Psychiatry 2001;40:504-505
24. Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 2004;14:350-358
25. Kleinberg DL, Davis JM, DeCoster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61